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Hypomethylation of DNA: A Possible
Nongenotoxic Mechanism Underlying the
Role of Cell Proliferation in Carcinogenesis
by Jay 1. Goodman' and Jennifer L. Counts1
DNA methylation (i.e., the 5-methylcytosin content of DNA) plays a role in the regulation of
gene activity. There is a persuasive body ofevidence indicating that differential methylation of
DNA (i.e., 5-methylcytosine versus cytosine) is a determinant of chromatin structure and that
the methyl group provides a chemical signal that is recognized by trans-acting factors that reg-
ulate transcription. Hypomethylation (i.e., low levels ofDNA 5-methylcytosine) of a gene is nec-
essary but not sufficient for its expression, and, therefore, a hypomethylated gene can be con-
sidered to possess an increased potential for expression as compared to a hypermethylated
gene. Cell proliferation is a fundamental component of carcinogenesis. It plays a key role in
expanding clones of initiated cells and, in addition, cell replication may contribute to carcino-
genesis by facilitating mutagenesis. This can occur either by causing the fixation of promuta-
genic DNA-damage before repair or as a consequence ofa "normal" error occurring during DNA
replication. During periods of cell proliferation the established pattern of DNA methylation is
maintained by the action of a maintenance methylase following DNA replication. Changes in
the methylation status ofa gene provide a mechanism by which its potential for expression can
be altered in an epigenetic heritable manner, and it is expected that modifications in DNA
methylation would result from threshold-exhibiting events.
Introduction
A decrease in DNA-5-methylcytosine (i.e., hypo-
methylation) may facilitate the aberrant expression of
protooncogenes involved in carcinogenesis. We are pro-
ceeding to test our hypothesis that hypomethylation of
DNA is a nongenotoxic mechanism underlying the role
ofcell proliferation in carcinogenesis. Clearly, mutagen-
esis appears to be involved in carcinogenesis. However,
with the possible exception oftumor-suppressor genes,
a mutated gene must be expressed to affect the pheno-
type of a cell. Therefore, our hypothesis is fully compat-
ible with, and complementary to, the notions of Cohen
and Ellwein (11) and Ames and Gold, (12) regarding the
role ofcell proliferation in carcinogenesis.
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Epigenetics and Consideration of
Inheritance on a Dual Level
Currently, we recognize the fact that there is a need
to consider inheritance on a dual level. That is, to dis-
tinguish the transmission of genes from generation to
generation (i.e., inheritance of DNA base sequence)
from the mechanisms involved in the transmission of
alternative states of gene activity in somatic cells.
"Epigenetics" is the term used to describe the latter,
and it may be defined as the study of mechanisms
responsible for the temporal and spatial control ofgene
activity, e.g., changes in gene expression during devel-
opment, segregation of gene activities such that
daughters of an individual cell have different patterns
of gene expression, and mechanisms to permit the
somatic inheritance ofa specific set ofactive and quies-
cent genes (1). DNA methylation is one epigenetic
mechanism by which gene activity may be regulated.
DNA Methylation and Regulation of
Gene Activity
DNA methylation (i.e., the 5-methylcytosine content
of DNA) plays a role in the regulation of gene activityGOODMANAND COUNTS
(2). There is a persuasive body of evidence indicating
that differential methylation of DNA (i.e., 5-methylcy-
tosine versus cytosine) is a determinant of higher-
order chromatin structure (3) and that the methyl
group provides a chemical signal that is recognized by
trans-acting factors. Binding or lack ofbinding ofthese
factors prevent transcription (1). Thus, DNA methyla-
tion appears to be a mechanism whereby cells can con-
trol the expression of genes with similar promoter
regions in the presence ofubiquitous transcription fac-
tors (4). Hypomethylation of a gene, i.e., low levels of
DNA 5-methylcytosine (DNA-5MeC), is necessary but
not sufficient for its expression. Therefore, a hypo-
methylated gene can be considered to possess an
increased potential for expression as compared to a
hypermethylated gene (5).
While methylation in the vicinity of the 5' end of a
gene often appears tobe involved in the regulation ofits
transcription, hypomethylation in the middle and in the
vicinity of the 3' end have also been correlated with
gene expression (6). This is illustrated in an elegant
series of studies in which it was demonstrated that the
capacity of a plasmid containing the human Ha-ras
oncogene, mutated by a G to Ttransversion at codon 12,
to transform NIH-3T3 cells was reduced 80% after
methylation in vitro at all ofits CCGG and GCGC sites
by the methyl transferases Hpall and Hhal, respective-
ly. Treatment ofthe plasmid with either ofthe methyl-
transferases alone had no effect (7). In addition, the
influence of methylation on gene expression was
assessed using an experimental system consisting of a
plasmid containing the chloramphenicol acetyltrans-
ferase (CAT) gene linked to either the Ha-ras gene pro-
moter region, which is enriched with CpG islands, or a
promoter consisting of the Rous sarcoma virus (RSV)
longterminal repeat (LTR), which does not contain CpG
islands (8). Methylation of the plasmids in vitro with
methyltransferases Hpall plus Hhal and with human
placental methyltransferase resulted in marked inhibi-
tion of expression. CAT expression was decreased
approximately 50% in those experiments in which the
LTR-containing plasmid was employed, while expres-
sion was reduced >95% when the Ha-ras gene promot-
er-containing plasmid was used (8). Taken together,
these studies indicate that regulation ofgene expression
can involve multiple methylatable cytosine-containing
sites in both the promoter region and in regions down-
stream of the transcription start site and that a high
percentage of these sites might have to be methylated
to render the gene completely quiescent. This is consis-
tent with recent observations indicating that the bind-
ing ofa repressor protein is correlated directly with the
density and distribution ofmethylated CpG sites (9).
Cell Proliferation, DNA Methylation,
and Carcinogenesis
In vivo, 5-methylcytosine is most often found in
DNA at CpG residues, and each site is actually modi-
fied on both strands (2), i.e., DNA methylation is sym-
metrical. During periods of cell proliferation, the
established pattern of DNA methylation is maintained
by the action of an S-adenosylmethionine-requiring
maintenance methylase. Immediately after DNA repli-
cation, the newly synthesized strand is unmodified
(i.e., not methylated). However, the maintenance
methylase is specific for hemimethylated sites (10),
and, therefore, it can maintain the normal symmetrical
pattern of DNA methylation. Thus, a CpG site that is
initially unmodified can remain that way after replica-
tion, while a methylated CpG site will be recognized
by the methyl group remaining on the parental strand
and be methylated on the complementary strand (2).
Changes in the methylation status of a gene provide a
mechanism by which its potential for expression can be
altered in an epigenetic heritable manner (1,4) and, in
light of the steps involved in DNA maintenance
methylation, it is expected that modifications in DNA
methylation would result from threshold-exhibiting
events.
Cell proliferation is a fundamental component of the
multistage process of carcinogenesis (11). It plays a
key role in expanding clones of initiated cells, and, in
addition, cell replication may contribute to carcinogen-
esis by facilitating mutagenesis (12). This can occur
either by causing the fixation of promutagenic DNA
damage before repair or as a consequence of a "nor-
mal" error occurring during DNA replication. In addi-
tion, during periods ofcell replication, and especially in
an animal chronically exposed to the maximum tolerat-
ed dose of a test compound, there is the possibility for
heritable decreases in DNA-5-MeC (i.e., hypomethyla-
tion) due to a limitation in the capacity for and/or
fidelity of DNA maintenance methylation. This is
expected to be a threshold-exhibiting event and could
result in a heritable, epigenetic, increase in the poten-
tial forgene expression.
We do not anticipate a simple one -to -one relation-
ship between the level of cell proliferation and hypo-
methylation of DNA. The ability to maintain the
nascent pattern ofmethylation is dependent on a com-
plex relationship between the capacity and fidelity of
DNA maintenance methylase, the amount of S-adeno-
sylmethionine, and the level ofcell proliferation.
Evidence for hypomethylation and cell replication
playing a role in carcinogenesis comes from studies
involving the use of a choline-devoid (CD) diet.
Fischer-344 rats (13,14) and B6C3F1 mice (15) develop
liver tumors, even without exposure to chemical car-
cinogens, after they are fed a CD diet. Dietary choline
and methionine are required to maintain hepatic intra-
cellular levels of S-adenosylmethionine, and a deple-
tion of this cofactor for methylation reactions might
lead to hypomethylation of DNA with concomitant
alterations in the expression of proto-oncogenes,
including Ha-ras (16). Alterations in DNA methylation
have been suggested to play a role in carcinogenesis
(17). Furthermore, increased liver cell proliferation, as
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measured by incorporation of 3H-[methyl]-thymidine
into DNA and an increase in the percent of hepato-
cytes in mitosis, can be detected within 1 week after
placing rats on a CD diet (18). This increased prolifera-
tion of hepatocytes was sustained during a 9-week
period while the animals were maintained on the CD
diet. Thus, a CD diet-induced decrease in S-adenosyl-
methionine levels in the presence ofincreased cell pro-
liferation may result in hypomethylation ofDNA.
Hypomethylation of DNA may facilitate the aber-
rant expression ofproto-oncogenes involved in carcino-
genesis. We are proceeding to test our hypothesis that
hypomethylation of DNA is one of the mechanisms
underlying the role ofcell proliferation in carcinogene-
sis (5,19). Clearly, mutagenesis appears to be involved
in carcinogenesis. However, with the possible excep-
tion of tumor-suppressor genes, a mutated gene must
be expressed to affect the phenotype of a cell.
Therefore, our hypothesis is fully compatible with, and
complementary to, the notions of Cohen and Ellwein
(11) and Ames and Gold (12) regarding the role of cell
proliferation in carcinogenesis.
Hypomethylation of DNA in Mouse
Liver Tumors
The liver tumor-prone B6C3F1 mouse (C57BL/6Y x
C3H/Hed), in conjunction with the more susceptible
C3H/He paternal strain and relatively resistant
C57BL/6 maternal strain, provides an excellent model
for studying mechanisms involved in carcinogenesis (19).
A relative decreased capacity for and/or fidelity ofDNA
maintenance methylation, in addition to a lower nascent
level of methylation, might contribute to the high sus-
ceptibility to liver tumorigenesis exhibited by certain
strains ofmice (e.g., C3H/He and B6C3F1). The presence
ofactivated oncogenes has been detected in both sponta-
neous and chemically induced B6C3F1 mouse liver
tumors, but notin normal liver. Further examination has
revealed that Ha-ras is involved in approximately one-
third to one-half of these tumors. However, a critical
mutation in the Ha-ras gene per se cannot be the herita-
ble characteristic that predisposes the B6C3F1 mouse to
development ofliver tumors because nascent liver tissue
does not possess this alteration.
Ha-ras in the liver of B6C3F1 and C3H/He mice
lacks a methylated site (5'-MeCCCG-3') that is present
in the gene in C57BL/6 liver, and hepatic Ha-ras
appears to possess an additional DNAse I hypersensi-
tive site in the B6C3F1 and C3H/He strains as com-
pared to the C57BL/6 strain (19). This indicates an
increased potential for expression of Ha-ras in the
hepatoma-prone strains which could, in part, account
for high propensity for liver tumor development in
these strains. In addition, this might account for the
high frequency with which an activated Ha-ras is asso-
ciated with B6C3F1 and C3H/He mouse liver tumors.
Furthermore, Ha-ras has been found to be hypomethy-
lated in B6C3F1 mouse liver tumors induced by a geno-
toxic compound (benzidine) or nongenotoxic com-
pounds (phenobarbital [PB] or chloroform) as well as in
spontaneous tumors (19), indicating that hypomethyla-
tion might be a common event involved in oncogene
activation.
The raf protooncogene encodes a serine-threonine
kinase implicated in signal transduction downstream
of, or independent of, Ha-ras (20). Elevated levels of
rafmRNA have been detected in rat liver tumors (21),
and rodent liver epithelial cells transfected with v-raf
exhibit a transformed phenotype (22). Therefore, rafis
a reasonable candidate for involvement in mouse liver
tumorigenesis, either in conjunction with Ha-ras or in
those situations when an activated Ha-ras gene is not
detected.
The methylation status of raf was assessed by
restriction of mouse liver DNA with methylation-sen-
sitive isochizomers and Southern blot analysis. An
Mspl restriction fragment length polymorphism was
seen as the presence of a 6.7 kb band in the hepatoma-
resistant C57BL/6 strain but not in the hepatoma-
prone C3H/He strain. This band is due to a specific 5'-
MeCCGG-3' site in raf in the resistant strain that is
not present in the hepatoma-prone strain, and this is
similar to our findings noted above for Ha-ras. The
hepatoma-prone B6C3F1 (C57BL/6Y x C3H/He&)
mouse inherits a raf allele from the C57BL/6 which
contains that 5'-MeCCGG-3' site. This site is unmethy-
lated in B6C3F1 liver tumors induced by PB (150
mg/kg/day for 2 years). However, the methylation sta-
tus of a 5'-CMeCGG-3' site in exon 12 was not altered.
These data, the first to suggest a role for rafin mouse
liver tumorigenesis, indicate that a selective hypo-
methylation of raf is associated with PB-induced
mouse liver tumorigenesis and that this might facili-
tate aberrant expression ofthe gene (23).
Conclusion
Taken together, the investigations discussed here
support our hypothesis that hypomethylation of DNA
is a nongenotoxic mechanism underlying the role ofcell
proliferation in carcinogenesis. This could facilitate the
aberrant expression of oncogenes that is believed to
play a role in the multistep process by which a normal
cell is transformed into frank malignancy. In recent
years it has become apparent that it is increasingly dif-
ficult to live with a bioassay-driven definition ofa car-
cinogen (11), i.e., a carcinogen is simply a chemical that
increases the incidence of tumors in a given tissue in a
given period of time in a bioassay. The answer to the
question of whether a chemical might act as a carcino-
gen depends on a variety offactors, including dose and
the test animal used. A rational approach toward
assessment of the carcinogenic potential that a chemi-
cal might pose requires the incorporation of biological
information (24). The testing ofthe hypothesis we have
presented and discussed here offers the potential to
provide the type ofmechanistic insight required.
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